Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AKTX 
Akari Therapeutics PLC (AKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.9% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 31.21M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.23 | 52 Weeks Range 0.85 - 4.22 | Updated Date 08/15/2025 |
52 Weeks Range 0.85 - 4.22 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.56% | Return on Equity (TTM) -112.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30050296 | Price to Sales(TTM) - |
Enterprise Value 30050296 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 32176400 | Shares Floating 11241645481 |
Shares Outstanding 32176400 | Shares Floating 11241645481 | ||
Percent Insiders 34.7 | Percent Institutions 1.16 |
Upturn AI SWOT
Akari Therapeutics PLC
Company Overview
History and Background
Akari Therapeutics PLC is a late-stage biopharmaceutical company focused on developing innovative therapies to treat autoimmune and inflammatory diseases with high unmet need. The company has undergone several strategic shifts, initially focusing on cancer before pivoting to complement inhibition for autoimmune disorders.
Core Business Areas
- Rare Diseases: Developing treatments for rare autoimmune and inflammatory diseases with high unmet need, focusing on complement inhibition.
Leadership and Structure
The leadership team consists of experienced biotech executives focused on clinical development and regulatory approval of their lead candidate, nomacopan. Details on the full organizational structure are not publicly available in sufficient detail.
Top Products and Market Share
Key Offerings
- Nomacopan: Nomacopan is Akari's lead product candidate, a recombinant small protein that specifically inhibits complement component C5. It is being developed for bullous pemphigoid (BP) and atypical hemolytic uremic syndrome (aHUS). Specific market share data is unavailable as the product is not yet approved, but BP and aHUS are significant markets with unmet needs. Competitors depend on the specific disease indication. In BP, competitors include corticosteroids and other immunosuppressants. In aHUS, competitors include Alexion's Soliris/Ultomiris.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The rare disease segment is growing due to increased awareness and regulatory incentives.
Positioning
Akari is positioned as a specialist in complement inhibition for rare autoimmune and inflammatory diseases. Its competitive advantage lies in its unique C5 inhibitor, nomacopan, and its focus on niche indications with high unmet need.
Total Addressable Market (TAM)
The TAM for Akariu2019s indications is significant, estimated to be in the billions of dollars across BP and aHUS. Akari is positioned to capture a meaningful share of this market if nomacopan is approved.
Upturn SWOT Analysis
Strengths
- Novel C5 inhibitor (Nomacopan)
- Focus on rare diseases with high unmet need
- Advanced clinical development program
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single product candidate
- History of losses
- Need for regulatory approval
Opportunities
- Potential regulatory approvals for Nomacopan in BP and aHUS
- Expansion into additional indications
- Partnerships with larger pharmaceutical companies
- Orphan drug designations and market exclusivity
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
- Funding constraints
Competitors and Market Share
Key Competitors
- ALXN
- JNJ
- LLY
Competitive Landscape
Akari faces significant competition from established pharmaceutical companies with approved therapies. Its success depends on demonstrating the superior efficacy and safety of Nomacopan.
Growth Trajectory and Initiatives
Historical Growth: Akari's historical growth is characterized by clinical development milestones and regulatory interactions rather than revenue growth.
Future Projections: Future growth depends on the successful development and commercialization of Nomacopan. Analyst projections are not available without access to a financial terminal.
Recent Initiatives: Recent initiatives include advancing Nomacopan through clinical trials for BP and aHUS, seeking regulatory approvals, and exploring potential partnerships.
Summary
Akari Therapeutics PLC is a high-risk, high-reward biopharmaceutical company focused on developing nomacopan for rare autoimmune diseases. The company's success hinges on the successful completion of clinical trials and regulatory approvals. Key risks include funding constraints and competition. The company is currently in a precarious stage, so needs to keep an eye on the threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Press releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-09-21 | CEO, President & Director Mr. Abizer Gaslightwala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.akaritx.com |
Full time employees 8 | Website https://www.akaritx.com | ||
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.